痘苗病毒/T7RNA聚合酶辅助的原核基因在真核细胞中的表达

痘苗病毒/T7RNA聚合酶这一瞬时表达系统由于具有很多优于其他表达系统的特点而被广泛地应用于表达外源蛋白.TB-Chen株轮状病毒的VP6 DNA编码片段插入到原核质粒pETL的噬菌体T7启动子和终止子之间,获得重组表达质粒pET-VP6.构建好的重组表达质粒pET-VP6通过脂质体转染到真核细胞MA104中,用携带噬...     

P[4]、P[6]和P[8]型轮状病毒VP8*核心区蛋白的表达和纯化

为进一步深入研究我国人群中轮状病毒主要流行的P[4]、P[6]和P[8]型毒株的受体结合特点及结构基础,本研究将P[4]、P[6]和P[8]型毒株VP8*核心区(VP8*core)基因分别构建到原核表达载体pGEX4T-1和pET30a中,利用大肠杆菌表达获得轮状病毒P[4]、P[6]和P[8]型毒株VP8*核心区蛋白,并通过亲和层析分别纯化得到VP8*core-GST融合蛋白和VP8*-his标签蛋白,SDS-PAGE显示蛋白大小分别为46kDa和20kDa。综上,本研究成功构建了pGEX4T-1-VP8*core和pET30a-VP8*core重组质粒,利用原核表达系统得到VP8*coreGST融合蛋白和VP8*core-his蛋白,为VP8*蛋白的功能和结构研究提供基础。     

A型口蹄疫病毒VP0基因的克隆及原核表达

从实验室冻存的含A型口蹄疫病毒的细胞中提取FMDV总RNA,通过RT-PCR获得cDNA.并根据FMDV全基因组序列设计了一对针对VP0基因的引物,通过PCR扩增得到目的基因VP0并亚克隆入pMD18-T载体.将鉴定出的阳性质粒和表达载体pET32a用BamH Ⅰ和HindⅢ双酶切回收后连接获得阳性重组质粒pET32-VP0.用IPTG诱导重组质粒表达目的蛋白VP0并用SDS-PAGE进行检测.表达产物用镍亲和树脂进行了纯化.结果证明,口蹄疫病毒VP0蛋白在大肠杆菌中获得了高效表达且表达产物得到了纯化,为实验室进一步的研究提供了重要的材料.     

Ⅲ型脊髓灰质炎病毒抗原表位嵌合蛋白的免疫学研究

目的:对以轮状病毒(RV)重组VP6蛋白为载体插入Ⅲ型脊髓灰质炎病毒(PV3)VP1蛋白上1个抗原表位(VP1的91~102、254和168位氨基酸残基)所构建的嵌合蛋白6F/PV3N1进行体外免疫学研究。方法:利用分子克隆和基因重组技术将PV3抗原表位插入RV载体蛋白,构建重组抗原表位嵌合蛋白表达质粒,转染大肠杆菌后表达重组蛋白,经SDS-PAGE确认表达产物,再通过Western印迹分析嵌合蛋白的抗原反应性。结果:用载体蛋白VP6F、轮状病毒Wa病毒株免疫的豚鼠血清抗体分别都能与VP6F和6F/PV3N1产生特异性结合;PV3免疫的豚鼠血清抗体只能与6F/PV3N1产生特异性结合,不能与VP6F产生特异性结合;PV1免疫的豚鼠血清抗体则不能与6F/PV3N1和VP6F产生特异性结合。结论:PV1、PV3之间不存在交叉反应现象,以RV VP6为载体构建的嵌合蛋白6F/PV3N1具有较好的免疫原性,为研发RV/PV3嵌合疫苗提供了基础。     

轮状病毒VP4抗原表位在VP6载体蛋白同一位点表达比较研究

目的:评价轮状病毒(RV)VP4两个抗原表位插入VP6载体蛋白同一位点所表达的重组嵌合蛋白免疫学性质及在研制嵌合蛋白疫苗中的意义。方法:采用分子克隆和基因重组技术将RV VP4的两个抗原表位插入到VP6载体蛋白同一位点上,构建重组抗原表达质粒,表达携带不同抗原表位的重组嵌合蛋白,用Western blot和中和试验分析重组嵌合蛋白的抗原反应性和免疫原性。结果:成功构建了两个嵌合蛋白表达质粒,并在大肠杆菌中高效表达;表达的嵌合蛋白可与相应抗体特异性反应;可诱导豚鼠产生特异性血清抗体;抗嵌合蛋白血清抗体可特异性识别载体蛋白VP6F,Wa株病毒的VP6和VP4蛋白,可中和Wa株病毒在MA104细胞上的感染性;结果表明,所构建和表达的两个以VP6为载体的VP4抗原表位嵌合蛋白具有较高抗原反应性和免疫原性;嵌合蛋白携带的VP4抗原表位具有增强载体蛋白免疫原性作用;为研制新型RV重组蛋白疫苗的奠定了较好的基础。     

杆状病毒AcMNPV vp39基因的克隆、表达与抗体制备

目的:构建苜蓿丫纹夜蛾核多角体病毒(Autographa californica nucleopolyhedro virus,AcMNPV)VP39的原核表达载体,表达、纯化蛋白并制备多克隆抗体。方法:用PCR方法扩增vp39基因,并将其克隆至pET-21a( )上,转化到大肠杆菌BL21(DE3)中进行诱导表达,采用割胶回收的方法纯化融合蛋白,纯化的融合蛋白作为抗原,免疫新西兰大白兔,Western blot检测抗体活性。结果:构建了pET-VP39原核表达质粒,含有该质粒的大肠杆菌经IPTG诱导超量表达了一个与预期理论值相符的约为40kDa的融合蛋白。对制备的抗体进行免疫印迹分析表明该抗血清能与感染苜蓿丫纹夜蛾核多角体病毒的细胞蛋白样品发生特异性反应。结论:获得了兔抗AcMNPV-VP39多克隆抗体,为进一步深入研究VP39在病毒侵染过程中与宿主因子的相互作用提供了检测工具。     

传染性法氏囊病病毒非结构蛋白VP5的原核表达及多克隆抗体的制备

利用PCR技术,从传染性法氏囊病病毒（IBDV）Gx,Gt毒株中分别扩增出VP5基因,将其克隆到表达载体pET30a、pET28a中。经PCR、酶切和序列分析鉴定获得重组质粒命名为pET28a-GtVP5、pET30a-GxVP5。将pET30a-GxVP5、pET28a-GtVP5分别转化宿主菌BL21(DE3),在IPTG诱导下均成功表达约24 kDa的Gx-VP5及23kDa的Gt-VP5融合蛋白,并都以包涵体形式存在。将Gx-VP5纯化后的蛋白免疫8周龄BALB/c雌鼠,ELISA分析表明制备的抗血清效价在1:25600以上,Western blot分析VP5表达产物能与抗6×His mAb及抗IBDV多克隆抗血清发生反应,具有良好的免疫反应特异性。     

成人腹泻轮状病毒蛋白的免疫印迹分析

我们从腹泻病人便样中纯化了病毒,其结构蛋白组分按分子量大小分别为VP1(136K),VP2(113K),VP3(92K),VP4(84K),VP5(64K),VP6(47K),VP7(41K)。所有这些蛋白皆具有抗原性。WP6是B组轮状病毒的共同抗原。B组轮状病毒的每一结构蛋白与A组轮状病毒都无交叉免疫反应。另外注意到二例不同病人对VP6和VP7刺激产生的抗体水平不同。     

A型塞内卡病毒的病毒样颗粒的制备及其免疫原性分析

为了研制A型塞内卡病毒 (Senecavirus A,SVA) 的病毒样颗粒 (Virus-like particles,VLPs) 疫苗,以SVA田间流行毒株CH-FJ-2017结构蛋白基因序列为研究对象,构建了能够同时表达SVA的3种结构蛋白VP0、VP1和VP3的单个原核重组表达质粒pET28a-SVA-VP031。通过大肠杆菌Escherichia coli表达、亲和层析纯化和体外自组装,获得SVA VLPs。透射电子显微镜鉴定显示,SVA的3种结构蛋白在体外能够自组装成直径约25–30 nm的VLPs,并且动物免疫试验结果表明,该VLPs能够有效刺激豚鼠产生高水平的抗原特异性中和抗体。上述研究结果为SVA VLPs疫苗的研制奠定了基础。     

人A组轮状病毒地方株外壳蛋白VP4的原核表达

目的：制备轮状病毒外壳蛋白VP4。方法：从病人粪便中分离的毒株中提取病毒dsRNA为模板,经RT—PCR获得编码VP4截短蛋白基因片段cDNA(1—1253bp),将VP4基因片段克隆于pGEX-4T-2融合表达载体中,经dot印迹筛出阳性重组子,重组质粒转化大肠杆菌BL21(DE3)。工程菌经IPTG诱导,11％聚丙烯酰胺凝胶电泳。结果：Western印迹分析表明,工程菌能正确表达VP4蛋白片段,且具有良好的抗原性。结论：为研制轮状病毒重组疫苗、亚单组疫苗、转基因植物口服疫苗做了前期准备。     

Cloning, expression, and purification of recombinant bovine rotavirus hemagglutinin, VP8*, in Escherichia coli

Rotavirus VP8* subunit is the minor trypsin cleavage product of the spike protein VP4, which is the major determinant of the viral infectivity and neutralization. To study the structure-function relationship of this fragment and to obtain type-specific reagents, substantial amounts of this protein are needed. Thus, full-length VP8* cDNA, including the entire trypsin cleavage-encoding region in gene 4, was synthesized and amplified by RT-PCR from total RNA purified from bovine rotavirus strain C486 propagated in MA104 cell culture. The extended VP8* cDNA (VP8ext) was cloned into the pGEM-T Easy plasmid and subcloned into the Escherichia coli expression plasmid pET28a(+). The correspondent 30 kDa protein was overexpressed in E. coli BL21(DE3)pLysS cells under the control of the T7 promoter. The identity and the antigenicity of VP8ext were confirmed on Western blots using anti-His and anti-rotavirus antibodies. Immobilized Ni-ion affinity chromatography was used to purify the expressed protein resulting in a yield of 4 mg of VP8ext per liter of induced E. coli culture. Our results indicate that VP8ext maintained its native antigenicity and specificity, providing a good source of antigen for the production of P type-specific immune reagents. Detailed structural analysis of pure recombinant VP8 subunit should allow a better understanding of its role in cell attachment and rotavirus tropism. Application of similar procedure to distinct rotavirus P serotypes should provide valuable P serotype-specific immune reagents for rotavirus diagnostics and epidemiologic surveys.     

The rhesus rotavirus outer capsid protein VP4 functions as a hemagglutinin and is antigenically conserved when expressed by a baculovirus recombinant.

Rhesus rotavirus (RRV) gene 4 was cloned into lambda bacteriophage, inserted into a polyhedrin promoter shuttle plasmid, and expressed in Sf9 cells by a recombinant baculovirus. The baculovirus-expressed VP4 protein made up approximately 5% of the Spodoptera frugiperda-infected cell protein. Monoclonal antibodies that neutralize the virus bound to the expressed VP4 polypeptide, indicating that the expressed VP4 protein was antigenically indistinguishable from viral VP4. In addition, we have determined that the baculovirus-expressed VP4 protein bound to erythrocytes and functions as the RRV hemagglutinin. The endogenous hemagglutinating activity of the VP4 protein, like the virus, was inhibited by guinea pig antirotavirus hyperimmune serum and by VP4-specific neutralizing monoclonal antibodies. The human erythrocyte protein, glycophorin, also inhibited hemagglutination by RRV or the expressed VP4 protein and appears to be the rotavirus erythrocyte receptor. The baculovirus-expressed VP4 protein was conserved functionally and antigenically in the absence of other outer or inner capsid rotavirus components and represents a logical candidate for future immunological studies.     

Intranasal administration of an Escherichia coli-expressed codon-optimized rotavirus VP6 protein induces protection in mice

We are developing rotavirus vaccines based on the VP6 protein of the human G1P[8] [corrected] [J. Virol. 73 (1999) 7574] CJN strain of rotavirus. One prototype candidate consisting of MBP::VP6::His6, a chimeric protein of maltose-binding protein, VP6 and hexahistidine, was expressed mainly as truncated polypeptides in Escherichia coli BL21(DE3) cells. A possible reason for this extensive truncation is the high frequencies of rare bacterial codons within the rotavirus VP6 gene. Expression of truncated recombinant VP6 was found to be reduced, and expression of complete VP6 protein was simultaneously increased, when the protein was expressed in Rosetta(DE3)pLacI E. coli cells that contain increased amounts of transfer RNAs for a selection of rare codons. The same observation was made when a synthetic codon-optimized CJN-VP6 gene was expressed in E. coli BL21 or Rosetta cells. To increase protein recovery, recombinant E. coli cells were treated with 8M urea. Denatured, full-length MBP::VP6::His6 protein was then purified and used for intranasal vaccination of BALB/c mice (2 doses administered with E. coli heat-labile toxin LT(R192G) as adjuvant). Following oral challenge with the G3P[16] [corrected] [J. Virol. 76 (2002) 560] EDIM strain of murine rotavirus, protection levels against fecal rotavirus shedding were comparable (P>0.05) between groups of mice immunized with denatured codon-optimized or native (not codon-optimized) immunogen with values ranging from 87 to 99%. These protection levels were also comparable to those found after immunization with non-denatured CJN VP6. Thus, expression of complete rotavirus VP6 protein was greatly enhanced by codon optimization, and the protection elicited was not affected by denaturation of recombinant VP6.     

Expression of the major capsid protein VP6 of group C rotavirus and synthesis of chimeric single-shelled particles by using recombinant baculoviruses.

VP6 of group C (Cowden strain) rotavirus was expressed in the baculovirus system. The recombinant protein, expressed to a high level in insect cells, was purified by ion-exchange chromatography. The purified protein was proven to be trimeric. The effect of pH on the trimer's stability was investigated. Coexpression of VP6 from group A (bovine strain RF) and VP6 from group C in the baculovirus system did not result in the formation of chimeric trimers. Coexpression of VP2 from group A rotavirus (bovine strain RF) and VP6 from group C in the baculovirus system led to the formation of chimeric, empty, single-shelled particles. These results demonstrate conservation in the domains necessary for binding to VP2 in different serogroups of VP6. The locations of the domains involved in trimerization and in the interaction with VP2 are discussed.     

在昆虫细胞中表达G2型轮状病毒地方株VP7基因

Ａ组轮状病毒是导致婴幼儿重症腹泻的最主要病毒病原,ＶＰ７是病毒外壳上的主要糖蛋白,它具有中和抗原活性,与病毒的毒力及免疫保护性有关,也是划分病毒血清型的最主要标志之一〔１〕。ＶＰ７基因及其编码蛋白一直是人们研究的主要对象,很多研究工作和诊断试剂都需大...     

Comparison of two eukaryotic systems for the expression of VP6 protein of rotavirus specie A: transient gene expression in HEK293-T cells and insect cell-baculovirus system

The VP6 protein of rotavirus A (RVA) is a target antigen used for diagnostic assays and also for the development of new RVA vaccines. We have compared the expression of VP6 protein in human embryonic kidney (HEK293-T) cells with results obtained using a well-established insect cell-baculovirus system. The recombinant VP6 (rVP6) expressed in HEK293-T cells did not present degradation and also retained the ability to form trimers. In the insect cell-baculovirus system, rVP6 was expressed at higher levels and with protein degradation as well as partial loss of ability to form trimers was observed. Therefore, HEK293-T cells represent a less laborious alternative system than insect cells for expression of rVP6 from human RVA.     

Immunization with baculovirus-expressed recombinant rotavirus proteins VP1, VP4, VP6, and VP7 induces CD8+ T lymphocytes that mediate clearance of chronic rotavirus infection in SCID mice.

Clearance of chronic murine rotavirus infection in SCID mice can be demonstrated by adoptive transfer of immune CD8+ T lymphocytes from histocompatible donor mice immunized with a murine homotypic rotavirus (T. Dharakul, L. Rott, and H.B. Greenberg, J. Virol 64:4375-4382, 1990). The present study focuses on the protein specificity and heterotypic nature of cell-mediated clearance of chronic murine rotavirus infection in SCID mice. Heterotypic cell-mediated clearance was demonstrated in SCID mice infected with EDIM (murine) rotavirus after adoptive transfer of CD8+ T lymphocytes from BALB/c mice that were immunized with a variety of heterologous (nonmurine) rotaviruses including Wa (human, serotype 1), SA11 and RRV (simian, serotype 3), and NCDV and RF (bovine, serotype 6). This finding indicates the serotypic independence of T-cell-mediated rotavirus clearance. To further identify the rotavirus proteins that are capable of generating CD8+ T cells that mediate virus clearance, donor mice were immunized with SF-9 cells infected with a baculovirus recombinant expressing one of the following rotavirus proteins: VP1, VP2, NS53 (from RF), VP4, VP7, NS35 (from RRV), VP6, and NS28 (from SA11). SCID mice stopped shedding rotavirus after receiving CD8+ T cells from mice immunized with VP1, VP4, VP6, and VP7 but not with VP2, NS53, NS35, NS28, or wild-type baculovirus. These results suggest that heterotypic cell-mediated clearance of rotavirus in SCID mice is mediated by three of the major rotavirus structural proteins and by a putative polymerase protein.     

A Recombinant Rotavirus Antigen Based on the Coat Protein of Alternanthera Mosaic Virus

Thanks to their strong immunostimulating properties and safety for humans, plant viruses represent an appropriate basis for the design of novel vaccines. The coat protein of Alternanthera mosaic virus can form virus-like particles that are stable under physiological conditions and have adjuvant properties. This work presents a recombinant human rotavirus A antigen based on the epitope of rotavirus structural protein VP6, using Alternanthera mosaic virus coat protein as a carrier. An expression vector containing the gene of Alternanthera mosaic virus (MU strain) coat protein fused to the epitope of rotavirus protein VP6 was designed. Immunoblot analysis showed that the chimeric protein was effectively recognized by commercial polyclonal antibodies to rotavirus and therefore is a suitable candidate for development of a vaccine prototype. Interaction of the chimeric recombinant protein with the native coat protein of Alternanthera mosaic virus and its RNA resulted in the formation of ribonucleoprotein complexes that were recognized by anti-rotavirus antibodies.     

A组轮状病毒G4型地方株VP7基因在杆状病毒系统中的表达

Ａ组轮状病毒是导致婴幼儿重症腹泻的最主要病毒病原,位于病毒外壳上的ＶＰ４和ＶＰ７蛋白具有中和抗原活性,与病毒的毒力及免疫保护性有关。ＶＰ７是外壳上的主要糖蛋白,根据其抗原性的不同,可将Ａ组轮状病毒划分出不同的血清型（Ｇ１～Ｇ１４）［１］,而对疫苗的研...